Last reviewed · How we verify
CKD-351
CKD-351 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
CKD-351 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers. Used for Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer.
At a glance
| Generic name | CKD-351 |
|---|---|
| Also known as | Latanoprost+D930 |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Selective Estrogen Receptor Degrader (SERD) |
| Target | Estrogen Receptor Alpha (ERα) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CKD-351 functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism differs from selective estrogen receptor modulators (SERMs) by achieving complete receptor elimination rather than partial antagonism. The drug is designed to overcome resistance mechanisms that develop with conventional endocrine therapies in estrogen receptor-positive breast cancer.
Approved indications
- Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer
Common side effects
- Hot flashes
- Vaginal dryness
- Fatigue
- Nausea
Key clinical trials
- A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 (PHASE2)
- A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 (PHASE3)
- Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-351 CI brief — competitive landscape report
- CKD-351 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI